Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications rather than financial performance data.
Material Changes
There are no material changes to financial performance reported in this filing. The only reported activity is an increase in share interests for specific individuals following a dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction where the Administrators of the SmithKline Beecham Mid-Term Incentive Plan notified the Company of an increase in Ordinary share ADRs at a price of $35.72 per ADR. This transaction resulted from the reinvestment of the dividend paid to shareholders on July 9, 2009.
Notable Transactions
- Mr E J Gray: Increase of 14.19 ADRs.
- Mr D J Phelan: Increase of 430.06 ADRs.
Investor Verification Checklist
- Verify the dividend payment date of July 9, 2009, in the company's broader financial announcements.
- Confirm the ADR price of $35.72 against market data for July 14, 2009.
- Review the full SmithKline Beecham Mid-Term Incentive Plan rules to understand the reinvestment mechanism.
- Check subsequent filings for the actual financial results for the period ending July 2009, as they are not included here.